Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE -3687.1%. (2020–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Market Cap | $102706 | $27M | $2M | — | — | — |
| Enterprise Value | $16M | $42M | $21M | — | — | — |
| P/E Ratio → | -0.01 | — | — | — | — | — |
| P/S Ratio | 0.01 | 1.60 | 0.14 | — | — | — |
| P/B Ratio | 0.12 | 17.02 | — | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.56 | 1.23 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Gross Margin | 19.8% | 19.8% | 21.3% | 25.9% | 32.5% | — |
| Operating Margin | -54.4% | -54.4% | -43.0% | -35.8% | -41.1% | — |
| Net Profit Margin | -86.0% | -86.0% | -88.7% | -49.9% | -52.2% | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| ROE | -3687.1% | -3687.1% | — | — | — | -25.1% |
| ROA | -67.9% | -67.9% | -70.5% | -37.0% | -41.9% | -25.1% |
| ROIC | -38.8% | -38.8% | -30.3% | -24.2% | -41.7% | — |
| ROCE | -68.9% | -68.9% | -52.9% | -40.8% | -89.3% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Debt / Equity | 10.48 | 10.48 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | 10.14 | — | — | — | -1.00 |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | -2.91 | -2.91 | -2.83 | -2.47 | -5.38 | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Current Ratio | 0.25 | 0.25 | 0.18 | 0.24 | 1.19 | — |
| Quick Ratio | 0.18 | 0.18 | 0.10 | 0.16 | 1.17 | — |
| Cash Ratio | 0.06 | 0.06 | 0.02 | 0.06 | 1.03 | — |
| Asset Turnover | — | 0.82 | 0.77 | 0.49 | 0.40 | — |
| Inventory Turnover | 25.74 | 25.74 | 22.96 | 12.52 | 41.95 | — |
| Days Sales Outstanding | — | 0.89 | 4.66 | 17.15 | 32.66 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 100.0% | 2.4% | 0.0% | — | — | — |
| Total Shareholder Yield | 100.0% | 2.4% | 0.0% | — | — | — |
| Shares Outstanding | — | $6M | $2677 | $4468 | $4468 | $4468 |
Imminent liquidity and solvency
According to recent market data, IVP trades at a price-to-book ratio of 0.12, a valuation level that suggests investors are pricing in significant asset impairment risks rather than future growth potential, as the company struggles to justify its current market capitalization against persistent net losses.
The lack of a meaningful P/E or EV/EBITDA multiple highlights that the market views the company as a distressed asset rather than a viable growth-oriented consolidator. This valuation discount appears to be a rational response to the company's inability to demonstrate a path toward positive earnings or sustainable cash flow generation.
Based on reported financial statements, IVP's ROIC has remained consistently negative, reaching -8.3% in 2025Q3, which indicates that the company is failing to generate any economic return on the capital deployed for its acquisition-heavy strategy, effectively destroying shareholder value with every additional clinic added.
The negative ROIC trend suggests that the premiums paid for veterinary practices are not being offset by operational improvements or synergies. Investors should monitor whether management can pivot toward organic efficiency, as the current model of compounding capital into loss-making assets appears fundamentally unsustainable.
As reported in recent filings, the company's cash conversion cycle remains highly volatile, with days payable outstanding reaching 232 days in 2025Q3, suggesting that IVP is relying heavily on extended supplier credit to manage its day-to-day operations due to a lack of internal cash generation.
The extreme reliance on DPO to manage working capital indicates a lack of leverage with vendors and a precarious liquidity position. This strategy may provide temporary relief, but it creates significant operational risk if suppliers tighten credit terms in response to the company's deteriorating financial health.
Based on the company's reported figures, the debt-to-equity ratio reached a peak of 39.16 in 2025Q2, illustrating an extreme reliance on external financing that leaves the company highly vulnerable to interest rate fluctuations and potential covenant breaches in the current high-cost capital environment.
The negative interest coverage ratios across recent quarters confirm that the company is unable to service its debt obligations from operating income. This leverage profile warrants intense scrutiny, as it suggests that the company may require dilutive equity financing or a distressed debt restructuring to avoid insolvency.
Investors frequently misapply price-to-sales multiples to IVP, which obscures the company's underlying margin distress and high fixed-cost structure, as top-line revenue growth is meaningless when the cost of acquiring and operating each additional clinic consistently exceeds the revenue generated at the point of service.
A more appropriate metric for this business model would be clinic-level EBITDA margins or free cash flow per location, which would better reflect the true earning power of the assets. Relying on P/S ratios in a roll-up model with negative margins can lead to a dangerous underestimation of the capital required to reach break-even.
Includes 30+ ratios · 5 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying IVP stock.
Inspire Veterinary Partners, Inc.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
Inspire Veterinary Partners, Inc.'s return on equity (ROE) is -3687.1%. The historical average is -25.1%.
Based on historical data, Inspire Veterinary Partners, Inc. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Inspire Veterinary Partners, Inc. has 19.8% gross margin and -54.4% operating margin.